The effect of curcumin on serum copper, zinc, and zinc/copper ratio in patients with β-thalassemia intermedia: a randomized double-blind clinical trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc and Copper (Supplement) in this randomized controlled trial publication.

Thalassemia intermedia is a subgroup of β-thalassemia which originates from mutations in the beta-globin gene.

Zinc and copper play important roles in the metabolism.

Who Took Part

According to the abstract, 30 patients were involved.

PubMed indexes the participants as young adults and adults, men only.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The patients were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

What Was Measured

The laboratory tests were checked at baseline and at the end of the treatment.

PubMed files the paper under topics including Blood Chemical Analysis, Capsules, Copper, Curcumin, Ferritins, Iran and Zinc.

The authors tagged it with the keywords Thalassemia intermedia.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc and Copper (Supplement) in 30 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2021 (Annals of hematology), a journal based in Germany.

More context: the Vitamin D, K2, Magnesium and Zinc compound page and the Copper (Supplement) compound page, all human trials.